Resistance to Targeted Therapies in Multiple Myeloma

Dr Ling is a clinical and laboratory haematologist of Liverpool hospital and NSW Pathology in NSW, Australia. She is a conjoint senior lecturer of the South Western Sydney Clinical School of UNSW Sydney and Western Sydney University. She is the leader of the Haematology Research Group in Ingham Institute of Applied Medical Research. She is the lead clinician of the myeloma stream in Liverpool Hospital, NSW, Australia. She is a member of the Medical & Scientific Advisory Group (MSAG) of Myeloma Australia and the myeloma working party of the Australasian Leukaemia and Lymphoma Group. She is an investigator of industry sponsored and academic clinical trials. Dr Ling received the degrees of MBBS and PhD from the University of Sydney. She is a fellow of the Royal Australasian College of Physicians and the Royal College of Pathologists of Australasia. She is a clinician scientist, with a focus on translational research in the mechanism of drug resistance in multiple myeloma. Her original research has been published in peer reviewed journals. She organises the teaching program of biomedical science of the South Western Sydney Clinical School of UNSW Sydney. She is a research supervisor of undergraduate and post-graduate students of UNSW Sydney and Western Sydney University. She is an invited reviewer of manuscripts, grants and examiner of masters and PhD thesis.Steven Trieu is a PhD candidate at the University of New South Wales, focused on drug resistance in multiple myeloma. He has received a Bachelor of Advanced Science with First-Class Honours from the University of New South Wales and is currently a recipient of an Australian Government Research Training Program Scholarship.Steven Trieu is a PhD candidate at the University of New South Wales, focused on drug resistance in multiple myeloma. He has received a Bachelor of Advanced Science with First-Class Honours from the University of New South Wales and is currently a recipient of an Australian Government Research Training Program Scholarship.

• 1. The role of targeted therapy in multiple myeloma.- 2. Lenalidomide.- 3. Pomalidomide.- 4. Mechanisms driving resistance to proteasome inhibitors bortezomib, carfilzomib and ixazomib in multiple myeloma.- 5. Daratumumab.- 6. Elotuzumab.- 7. Histone deacetylase inhibitors.- 8. Bone targeted therapies.- 9. New targeted therapies for multiple myeloma under clinical investigation.